We are live on ! Find out more
UTMD icon

Utah Medical Products
UTMD

93 hedge funds and large institutions have $238M invested in Utah Medical Products in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

27% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 26

3% more funds holding

Funds holding: 90 → 93 (+3)

2.92% more ownership

Funds ownership: 71.07% → 73.99% (+2.9%)

4% less capital invested

Capital invested by funds: $247M → $238M (-$9.01M)

Holders
93
Holders Change
+3
Holders Change %
+3.33%
% of All Funds
1.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
33
Reduced
26
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$2.62M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.53M
4
Millennium Management
Millennium Management
New York
+$1.88M
5
HR
Hayden Royal
North Carolina
+$1.05M

Top Sellers

Rank Fund Capital Flow
1
ProShare Advisors
ProShare Advisors
Maryland
-$11.6M
2
AA
Ancora Advisors
Ohio
-$848K
3
UBS Group
UBS Group
Switzerland
-$812K
4
TAM
THB Asset Management
Connecticut
-$801K
5
KFA
Krane Funds Advisors
New York
-$721K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCP
51
Seizert Capital Partners
Michigan
$287K -$42.2K -470 -13%
ASN
52
Advisory Services Network
Georgia
$254K -$185K -2,058 -42%
US Bancorp
53
US Bancorp
Minnesota
$244K -$53K -590 -18%
Deutsche Bank
54
Deutsche Bank
Germany
$240K +$43.1K +480 +22%
Invesco
55
Invesco
Georgia
$236K -$599K -6,672 -71%
Los Angeles Capital Management
56
Los Angeles Capital Management
California
$236K +$239K +2,665 New
Goldman Sachs
57
Goldman Sachs
New York
$220K -$1.89K -21 -0.8%
Two Sigma Advisers
58
Two Sigma Advisers
New York
$204K – – –
Morgan Stanley
59
Morgan Stanley
New York
$187K +$70.6K +787 +60%
AIG
60
American International Group
New York
$185K +$2.42K +27 +1%
SG Americas Securities
61
SG Americas Securities
New York
$181K +$61.6K +686 +51%
OSAM
62
O'Shaughnessy Asset Management
Connecticut
$180K +$113K +1,259 +164%
MIM
63
MetLife Investment Management
New Jersey
$177K – – –
IA
64
IndexIQ Advisors
New York
$167K -$18.2K -203 -10%
Barclays
65
Barclays
United Kingdom
$167K +$169K +1,887 New
TRCT
66
Tower Research Capital (TRC)
New York
$140K +$142K +1,581 New
Bank of America
67
Bank of America
North Carolina
$139K +$51K +568 +56%
MLICM
68
Metropolitan Life Insurance Company (MetLife)
New York
$122K – – –
DZ Bank
69
DZ Bank
Germany
$106K -$99.7K -1,111 -48%
Legal & General Group
70
Legal & General Group
United Kingdom
$105K – – –
UBS Group
71
UBS Group
Switzerland
$104K -$812K -9,049 -89%
MDCM
72
Morgan Dempsey Capital Management
Wisconsin
$82K -$9.88K -110 -11%
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$80K – – –
DA
74
Denali Advisors
California
$69K – – –
Lazard Asset Management
75
Lazard Asset Management
New York
$67K – – –
1 2
3
4 5

UTMD Hedge Fund Activity: Q2 2020 in Review

93 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q2 2020, worth a combined $238M — down 3.6% from $247M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new UTMD positions and 9 closed out — a net gain of 3 holders — while 33 added to existing stakes and 26 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.1M. The largest seller was ProShare Advisors, exiting entirely with an estimated $11.6M sold.

  • 93 institutional investors held Utah Medical Products (UTMD) as of Q2 2020, up from 90 in Q1 2020.
  • Funds reported $238M of Utah Medical Products stock for Q2 2020, down 3.6% quarter-over-quarter.
  • 12 funds opened new Utah Medical Products positions in Q2 2020 and 9 closed out, a net change of +3 holders.
  • The largest Utah Medical Products buyer in Q2 2020 was Fidelity Investments, an estimated $10.1M added.
  • The largest Utah Medical Products seller in Q2 2020 was ProShare Advisors, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2020.